Intralesional collagenase Clostridium histolyticum vs. verapamil injections in males with Peyronie’s Disease: A prospective, matched-pair, non-blinded, randomised clinical study comparing clinical outcomes and patient satisfaction rates

다국어 초록 (Multilingual Abstract)

Purpose: To compare clinical outcomes and patient satisfaction rates between intralesional verapamil (ILV) and collagenase Clostridium histolyticum (CCH) injections in males with Peyronie’s disease (PD).
Materials and Methods: Following ethics approval, PD patients were prospectively enrolled in this open-label non-blinded study. Patients were randomised to receive ILV or CCH injections with penile remodelling every fortnightly for 6 courses. Patient demographics, change in penile curvature, International Index of Erectile Function-15 and Peyronie’s Disease Questionnaire (PDQ) scores as well as overall patient satisfaction and Patient Global Impression of Improvement (PGI-I) scores were recorded at pre-treatment and 6-, 12- and 24-month post-treatment.
Results: A total of 50 males were recruited and divided into ILV (n=25) and CCH (n=25) groups. The mean changes in penile curvature were -16.8 (standard deviation [SD] 7.65) degrees in ILV and -28.2 (SD 11.5) degrees in CCH groups (p<0.01). Patients in the CCH group scored better than the ILV group on the PDQ psychosexual symptoms (-2.14 vs. -2.9; p<0.01) and symptom bother score (-3.88 vs. -4.16; p=0.08). Minor treatment-related adverse events were more common in the CCH group. The overall satisfaction rate on a 5-point scale was 4.1 in ILV and 4.5 in CCH groups, and there was no statistically significant difference in the PGI-I scores between the 2 groups (p=0.14).
Conclusions: CCH therapy is more effective than ILV to treat a carefully selected group of males with PD, with a reasonable safety profile and a higher high level of patient satisfaction rate in the short term.

참고문헌 (Reference)

1 Russell S, "Systematic evidence-based analysis of plaque injection therapy for Peyronie’s disease" 51 : 640-647, 2007

2 Cocci A, "Sildenafil 25 mg ODT + collagenase clostridium hystoliticum vs collagenase clostridium hystoliticum alone for the management of Peyronie’s disease : a matched-pair comparison analysis" 15 : 1472-1477, 2018

3 Hellstrom WJG, "Safety profile of collagenase Clostridium Histolyticum stratified by degree of penile curvature in patients with Peyronie disease" 106 : 237.e9-237.e14, 2017

4 Abdel Raheem A, "Safety and effectiveness of collagenase Clostridium histolyticum in the treatment of Peyronie’s disease using a new modified shortened protocol" 120 : 717-723, 2017

5 YafiFA, "Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase Clostridium histolyticum for Peyronie’s Disease" 13 : 684-689, 2016

6 Chung E, "Peyronie’s disease and mechanotransduction : an in vitro analysis of the cellular changes to Peyronie’s disease in a cell-culture strain system" 10 : 1259-1267, 2013

7 Nehra A, "Peyronie’s disease : AUA guideline" 194 : 745-753, 2015

8 Cavallini G, "Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie’s disease" 69 : 950-954, 2007

9 Beilan JA, "Intralesional injection of collagenase Clostridium histolyticum may increase the risk of late-onset penile fracture" 6 : 272-278, 2018

10 Anderson MS, "Inhibition of Peyronie’s plaque fibroblast proliferation by biologic agents" 12 (12): S25-S31, 2000

11 Chung E, "Evidence-based management guidelines on Peyronie’s Disease" 13 : 905-923, 2016

12 Alom M, "Efficacy of combined collagenase Clostridium histolyticum and RestoreX penile traction therapy in men with Peyronie’s disease" 16 : 891-900, 2019

13 Shirazi M, "Effect of intralesional verapamil for treatment of Peyronie’s disease : a randomized single-blind, placebo-controlled study" 41 : 467-471, 2009

14 Russo GI, "Comparative effectiveness of intralesional therapy for Peyronie’s disease in controlled clinical studies : a systematic review and network meta-analysis" 16 : 289-299, 2019

15 Gabrielson AT, "Collagenase Clostridium histolyticum in the treatment of urologic disease : current and future impact" 6 : 143-156, 2018

16 Capece M, "Collagenase Clostridium histolyticum for the treatment of Peyronie’s disease : a prospective Italian multicentric study" 6 : 564-567, 2018

17 Desai SS, "Collagenase Clostridium histolyticum for Dupuytren’s contracture" 10 : 1395-1404, 2010

18 Gelbard M, "Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies" 190 : 199-207, 2013

19 Russo GI, "Clinical efficacy of injection and mechanical therapy for Peyronie’s disease : a systematic review of the literature" 74 : 767-781, 2018

20 Carson CC 3rd, "Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum(CCH)for adults with Peyronie’s disease(PD)" 116 : 815-822, 2015

21 Chung E, "A state-of-art review on collagenase Clostridium histolyticum and Peyronie’s disease : drug profile, clinical evidence and safety outcomes" 20 : 559-564, 2020

22 Sadagopan A, "A snapshot of intralesional verapamil injection in the treatment of Peyronie’s disease today" 51 : e13388-, 2019

23 Chung E, "A comparative study of the efficacy of intralesional verapamil versus normal saline injection in a novel Peyronie disease animal model : assessment of immunohistopathological changes and erectile function outcome" 189 : 380-384, 2013

24 Chung E, "A clinical pathway for the management of Peyronie’s disease: integrating clinical guidelines from the International Society of Sexual Medicine, American Urological Association and European Urological Association" 126 (126): 12-17, 2020